Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

By J. Feld, I. Jacobson, C. Hézode, T. Asselah, P. Ruane, N. Gruener, A. Abergel, A. Mangia, Ching‐lung Lai, H. L. Chan and 14 more. New England Journal of Medicine, 2015

1,329 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/c86fa854e501cb285f7c6e0e16bb1706eacba30d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. A. Aghemo
2. G. Dusheiko
3. M. Puoti
4. J. Pawlotsky

Citations in the corpus

• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015, neutral): “Relapse 0 6/132 (5) 11/276 (4) 38/272 (14)”
• EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, background): “thirds) and treatment-experienced (one-third) patients infected with HCV genotype 2, of whom approximately 30% had cirrhosis.(127) In the phase III ASTRAL-2 trial in patients with HCV”
• Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, background): “Several well-designed, robust clinical trials have demonstrated the safety(147) and high curative efficacy of glecaprevir/pibrentasvir(148-158) and sofosbuvir/ velpatasvir(159-164) among treatment-naive persons without cirrhosis regardless of HCV genotype.”